The Latest Cardiac and Vascular News
SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass, Inc., today announced it has received conditional approval of its investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for percutaneous femoropopliteal bypass, DETOUR II will evaluate the safety and effectiveness of the DETOUR System […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ DETOUR System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late breaking clinical trial session today at Vascular InterVentional Advances (VIVA 17) by Dr. Sean Lyden, chairman […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass today announced that data from a subset analysis of the DETOUR I clinical trial will be presented during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), taking place September 11-14 in Las Vegas. The study evaluated the safety and effectiveness of the DETOUR System for treating long-segment (>25cm) […]
LONDON, Aug. 31, 2017 /PRNewswire/ — Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass’ DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around extremely long blockages in the upper leg arteries to restore blood flow to the lower […]
